Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $290.28M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.90M
Average 0.38M
Returns on capital
Evommune, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.5%
avg 18.9%
ROIC
-39.0%
avg -77.1%
ROA
-30.6%
avg -53.3%
Analysis
ROA is currently the strongest return metric at -30.6% versus its period average of -53.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Luis C. Pena | Founder, President, Chief Executive Officer & Director | USD 1.33M | 63 | 631.57K | 4.46% |
Gregory S. Moss | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer | USD 1.03M | 42 | — | — |
Kyle Carver | Chief Financial Officer | USD 1.01M | 38 | 60.34K | 0.43% |
Lou Sehl | Senior Vice President of Technical Operations | — | — | — | — |
Janice Drew | Chief of Development Operations | — | 63 | — | — |
Eugene Andrew Bauer | Co-Founder, Chief Medical Officer & Director | — | 84 | — | — |
Daniel J. Burge | Senior Vice President of Clinical Development | — | 64 | — | — |
J. Mark Jackson | Senior Vice President of Clinical Development | — | — | — | — |
Jeegar Patel | Chief Scientific Officer | — | 48 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$146,260.00
Sells
3
$654,996.98
Net Transaction Value
−$508,736.98
Net selling
Most Active
Carver Kyle
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 8, 26Jul 8, 2026 | Carver Kyle Direct | Buy | $13.3K$13,260.00 |
| Jul 7, 26Jul 7, 2026 | KIRSCH ARTHUR S Indirect | Buy | $133K$133,000.00 |
| Jun 22, 26Jun 22, 2026 | Drew Janice Suzann Direct | Sell | $452.6K$452,600.00 |
| Jun 22, 26Jun 22, 2026 | Patel Jeegar Pravinkumar Direct | Sell | $33.5K$33,480.00 |
| Jun 22, 26Jun 22, 2026 | Pena Luis C. Direct | Sell | $168.9K$168,916.98 |
Summary
Insiders reported 2 buys worth $146,260.00 and 3 sells worth $654,996.98 over the last 12 months. That adds up to net selling of $508,736.98. Carver Kyle was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | -10.8% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at -10.8% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Evommune, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about EVMN's management, answered from reported figures.
Who manages EVMN?
Evommune, Inc. (EVMN) lists 9 active executives. The top listed executive is Lou Sehl, Senior Vice President of Technical Operations.
Are EVMN insiders buying or selling?
Recent insider activity shows net selling of $500,909.68.
Continue the stock analysis
Jump to another research area for this company.